OrbiMed Advisors acquires 1,000,000 Scribe Therapeutics shares valued at $15 million
SCTX•OrbiMed Advisors reports larger indirect holding in Scribe Therapeutics
OrbiMed Advisors, a Scribe Therapeutics director, reported an increase in indirect common-stock holdings to 1,348,825 shares.
The filing shows the acquisition of 1 million common shares at USD 15.
